The Patent Finder
US

Novel Lipids and Compositions for the Delivery of Therapeutics

US 10,117,941 Grace period ended
OverviewFamilyAssignmentsSources & methods

Also listed on Alnylam Pharmaceuticals, Inc., an earlier holder on the record. The recorded assignments below show how it moved.

Term ends Nov 10, 2029 · Low confidence

Grace period ended Nov 6, 2026 · no payment on record as of the Nov 17, 2026 fee file · lapse expected

Filed May 23, 2017 as application 15/603,069 · Granted Nov 6, 2018
Base term, 20 years from filing
Today
20 years from filing
2009 2029
Clock starts
Nov 10, 2009
Term ends
Nov 10, 2029
Granted
Nov 6, 2018
base term fee events Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 9,682,139, to Nov 10, 2029. The term already ends on or before that date, so the cap shortened nothing.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: Low: the grace period for its second maintenance fee ended Nov 6, 2026 with no payment on record. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Nov 10, 2009, when application PCT/US2009/063931, the earliest non-provisional in its chain, was filed (this one was filed May 23, 2017)Nov 10, 2029High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 9,682,139)resolves to Nov 10, 2029, no earlier than this term, so no changeHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee eventsRead from the payments on the fee record: none for this window, and its grace period has ended. No fee event states a lapse, and USPTO's status still reads "Patented Case".grace period ended Nov 6, 2026Low confidence
Computed term endThe steps above, in orderNov 10, 2029Low confidence

This family

Application PCT/US2009/063931PCT application
no patent term
no patent term
US 8,999,351In force
Nov 2030
Nov 2030
US 9,682,139Lapsed on the fee record
Jun 2025
Jun 2025
US 10,117,941this patent
Nov 2029
Nov 2029
US 10,821,186In force
Nov 2029
Nov 2029
Application 17/065,208Abandoned
not computed
not computed
Application 18/110,791Abandoned
not computed
not computed
Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Aug 10, 2017
Reel 43262, frame 674
Manoharan, Muthiah; Rajeev, Kallanthottathil G.; Jayaraman, Muthusamy; Nair, Jayaprakash K.; Maier, Martin; Butler, David; Eltepu, LaxmanAlnylam Pharmaceuticals, Inc.Assignment of Assignor's Interest
Aug 10, 2017
Reel 43262, frame 728
Alnylam Pharmaceuticals, Inc.Tekmira Pharmaceuticals CorporationAssignment of Assignor's Interest
Aug 10, 2017
Reel 43262, frame 788
Tekmira Pharmaceuticals CorporationArbutus Biopharma CorporationChange of Name
Jul 27, 2018
Reel 46640, frame 764
Protiva Biotherapeutics Inc.; Arbutus Biopharma CorporationArbutus Biopharma CorporationMerger and Change of Name

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited